1337258
Last Update Posted: 2017-05-30
Recruiting has ended
Males accepted | 50 Years-75 Years |
1 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Economic Analyses of the REDUCE Trial
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment.
The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.
Eligibility
Relevant conditions:
Neoplasms, Prostate
Benign Prostatic Hyperplasia
Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov